0000000000287934

AUTHOR

Etienne Allauze

showing 2 related works from this author

Association between anhedonia and suicidal events in patients with mood disorders: A 3-year prospective study.

2020

Background As almost all mental disorders are associated with increased suicidal-related behavior, anhedonia might be a trans-diagnostic dimension to target for suicide prevention. Methods For this 3-year-long prospective study, 2,839 outpatients with mood disorders were recruited. They were divided in: (a) two groups according to the occurrence or not of suicidal ideation during the follow-up, and (b) two groups according to the occurrence or not of suicide attempts during the follow-up. Anhedonia was assessed using a composite score (the French version of the 14-item Snaith-Hamilton Pleasure Scale and item 13 of the Quick Inventory of Depressive Symptomatology scale) at inclusion and at 6…

Anhedoniamedia_common.quotation_subjectSuicide Attemptedbehavioral disciplines and activitiesSuicide preventionPleasureSuicidal Ideation03 medical and health sciences0302 clinical medicineRisk FactorsmedicineHumansProspective StudiesSuicidal ideationComputingMilieux_MISCELLANEOUSmedia_commonSuicide attemptbusiness.industryMood DisordersAnhedoniaOdds ratiomedicine.disease030227 psychiatryPsychiatry and Mental healthClinical PsychologyMood disordersMarital status[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]medicine.symptombusiness030217 neurology & neurosurgeryClinical psychologyDepression and anxietyREFERENCES
researchProduct

Treatment-resistant depression in a real-world setting: first interim analysis of characteristics, healthcare resource use, and utility values of the…

2020

Background: Major depressive disorder (MDD) is among the most common psychiatric disorders. One-third of patients are usually unresponsive to several lines of treatment. This study aimed to describe the FondaMental French cohort of patients with treatment-resistant depression (TRD) and to estimate utility and healthcare resource use outcomes. Methods: Patients with TRD were evaluated prospectively over four years (baseline, 6, 12, 18, 24, 36 and 48 months) in a real-world clinical setting. Interim analyses focused on the first two consecutive years. Four MDD-related states (major depressive episode (MDE), response, remission, recovery) were defined based on the MADRS (Montgomery&ndash

medicine.medical_specialtyreal-world[SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthArticlelcsh:RC321-57103 medical and health sciences0302 clinical medicinehealthcare resource useQuality of lifeRating scaleInternal medicineMedicine[SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Major depressive episodelcsh:Neurosciences. Biological psychiatry. NeuropsychiatryDepression (differential diagnoses)business.industryGeneral Neurosciencemedicine.diseaseInterim analysis3. Good health030227 psychiatryutility[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie[SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthCohorttreatment-resistant depressionMajor depressive disorder[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC][SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiemedicine.symptombusinessTreatment-resistant depression030217 neurology & neurosurgery
researchProduct